Usefulness of Progesterone-Only Components for Contraception in Patients With Congenital Heart Disease

详细信息    查看全文

• 作者：Antonia Pijuan-Dom¨¨nech ; Francesc Bar¨®-Marin¨¦ ; Mireia Rojas-Torrijos ; Laura Dos-Subir¨¤ ; Valle Pedrosa-Del Moral ; Maria Teresa Subirana-Dom¨¨nech ; Maria Goya-Canino ; Luis Cabero-Roura ; David Garcia-Dorado ; Jaume Casald¨¤liga-Ferrer
• 刊名：The American Journal of Cardiology
• 出版年：2013
• 出版时间：15 August, 2013
• 年：2013
• 卷：112
• 期：4
• 页码：590-593
• 全文大小：260 K

文摘

The objective of the study is to report the contraceptive methods used by patients with congenital heart disease (CHD) before referral to a specific preconception clinic and evaluate safety and treatment adherence of the alternative contraception method, progesterone-only component (PC), offered. Contraceptive methods in the CHD population reported included estrogen-progesterone combined contraceptives (EPCC), despite the potential risk for thromboembolism. PC has been suggested as an alternative, but, no information on its use has been reported. Retrospective analysis was performed of all patients (n?= 237) referred to the preconception clinic of an adult CHD center. Thirty-three percent of patients had used EPCC in the past; 3.8 % had had thromboembolic events during its use. Current contraception consisted of barrier methods in 58 % of patients, EPCC in 18 % , and PC in 1.3 % ; 21.7 % of patients were not using any contraception. PC was offered as an alternative in 146 patients; 73 % of patients agreed to start the treatment. At a median follow-up of 1 year, 73 % of patients who started PC maintained the treatment. Gynecologic side effects were reported in 25 % of patients, with no cardiovascular effects. In conclusion, a significant proportion of patients with CHD were former users of EPCC, although some had formal contraindications, and the rate of PC use before referral to the preconception clinic was low. After being offered as an alternative treatment, the use of PC in its various forms was extensive, with no thrombogenic side effects and an acceptable rate of gynecologic side effects being reported.